No Data
No Data
ZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100
Express News | ZyVersa Therapeutics Q1 EPS $(0.73) Misses $(0.40) Estimate
10-Q: Quarterly report
Press Release: ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
ZyVersa Announces Release Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Unmet Medical Needs Of People Living With Obesity
Express News | Zyversa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination With GLP-1 Agonists to Address Unmet Medical Needs of People Living With Obesity; Provides R&D Update